One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Eli Lilly and Company logo
Eli Lilly and Company LLY
$ 1 345.4 -0.53%
report update icon

Quarterly report 2026-Q3
added 10-29-2026

Eli Lilly and Company Financial Statements 2025-2006 | LLY

Annual Financial Statements Eli Lilly and Company

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

Market Cap

940 B 780 B 665 B 297 B 226 B 182 B 137 B 120 B 90.6 B 82.2 B 87.4 B 80 B 59.5 B 62.1 B 43.7 B 36 B 38.1 B 52.1 B - -

Shares

897 M 901 M 900 M 902 M 907 M 908 M 958 M 1.03 B 1.05 B 1.1 B 1.11 B 1.11 B 1.12 B 1.15 B 1.11 B 1.11 B 1.1 B 1.09 B - -

Historical Prices

1.05 K 866 738 329 249 201 121 119 70.7 74 62.3 59.1 48.6 43 29.5 32.5 34.7 47.6 58.9 52

Net Income

20.6 B 10.6 B 5.24 B 6.24 B 5.58 B 6.19 B 8.32 B 3.23 B -204 M 2.74 B 2.41 B 2.39 B 4.68 B 4.09 B 4.35 B 5.07 B 4.33 B -2.07 B 2.95 B -

Revenue

65.2 B 45 B 34.1 B 28.5 B 28.3 B 24.5 B 22.3 B 24.6 B 22.9 B 21.2 B 20 B 19.6 B 23.1 B 22.6 B 24.3 B 23.1 B 21.8 B 20.4 B 18.6 B -

Cost of Revenue

11.1 B 8.42 B 7.08 B 6.63 B 7.31 B 5.48 B 4.72 B 4.68 B 4.45 B 4.16 B - - - - - - - - - -

Gross Profit

54.1 B 36.6 B 27 B 21.9 B 21 B 19.1 B 17.6 B 18.1 B 16.8 B 15.6 B 14.9 B 14.7 B 18.2 B 17.8 B 19.2 B - - - - -

Interest Expense

- -25.4 M 486 M 332 M 340 M 360 M 401 M 242 M 225 M 185 M 161 M 149 M 160 M 178 M 186 M 186 M 261 M -228 M 122 M -

EBITDA

2 B 1.77 B 1.53 B 1.52 B 1.55 B 1.32 B 7.02 B 7.8 B 5.98 B 5.37 B 5.02 B 4.71 B 6.99 B 6.48 B 7.69 B 1.33 B 1.3 B 1.12 B -1.05 B -

Operating Expenses

54.1 B 36.6 B 27 B 21.9 B 21 B 19.1 B 11.8 B 11.9 B 12.4 B 11.7 B 11.3 B 11.4 B 12.7 B 12.8 B 12.9 B - - - - -

General and Administrative Expenses

11.1 B 8.59 B 7.4 B 6.44 B 6.43 B 6.12 B - - 514 M - - - - - 7.88 B 7.05 B 6.89 B 6.63 B 6.1 B -

All numbers in USD currency

Quarterly Income Statement Eli Lilly and Company

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2010-Q3 2010-Q2 2010-Q1 2009-Q4 2009-Q3 2009-Q2

Shares

892 M 892 M 894 M -500 K 897 M 898 M 899 M -300 K 901 M 901 M 901 M - 900 M 900 M 901 M -64 K 901 M 900 M 904 M -737 K 907 M 907 M 909 M 134 K 907 M 907 M 908 M -7.14 M 914 M 921 M 980 M -5.48 M 1.02 B 1.03 B 1.05 B -2.78 M 1.05 B 1.06 B 1.06 B - 1.06 B 1.06 B 1.06 B - 1.06 B 1.06 B 1.06 B - 1.07 B 1.07 B 1.07 B - 1.08 B 1.08 B 1.09 B - - - - - - - - - - - - - - -

Net Income

6.45 B 7.1 B 7.4 B 6.64 B 5.58 B 5.66 B 2.76 B 4.41 B 970 M 2.97 B 2.24 B 2.19 B -57.4 M 1.76 B 1.34 B 1.94 B 1.45 B 952 M 1.9 B 1.73 B 1.11 B 1.39 B 1.36 B 2.12 B 1.21 B 1.41 B 1.46 B 1.5 B 1.25 B 1.33 B 4.24 B 1.13 B 1.15 B -260 M 1.22 B -1.66 B 556 M 1.01 B -111 M 772 M 778 M 748 M 440 M 478 M 800 M 601 M 530 M 428 M 501 M 734 M 728 M 728 M 1.2 B 1.21 B 1.55 B 827 M 1.33 B 924 M 1.01 B - 1.24 B 1.2 B 1.06 B - 1.3 B 1.35 B 1.25 B - 942 M 1.16 B

Revenue

24.4 B 23 B 19.8 B 19.3 B 17.6 B 15.6 B 12.7 B 13.5 B 11.4 B 11.3 B 8.77 B 9.35 B 9.5 B 8.31 B 6.96 B 7.3 B 6.94 B 6.49 B 7.81 B 8 B 6.77 B 6.74 B 6.81 B 7.44 B 5.74 B 5.5 B 5.86 B 6.11 B 5.48 B 5.64 B 5.09 B 5.64 B 5.31 B 5.58 B 4.96 B 6.16 B 5.66 B 5.82 B 5.23 B 5.76 B 5.19 B 5.4 B 4.87 B 5.38 B 4.96 B 4.98 B 4.64 B 5.12 B 4.88 B 4.94 B 4.68 B 5.81 B 5.77 B 5.93 B 5.6 B 5.96 B 5.44 B 5.6 B 5.6 B - 6.15 B 6.25 B 5.84 B - 5.65 B 5.75 B 5.49 B - 5.56 B 5.29 B

Cost of Revenue

3.93 B 3.27 B 3.58 B 3.37 B 3.01 B 2.45 B 2.22 B 2.4 B 2.17 B 2.17 B 1.67 B 1.79 B 1.86 B 1.81 B 1.63 B 1.55 B 1.58 B 1.43 B 2.07 B 2.05 B 1.43 B 1.95 B 1.88 B 1.72 B 1.33 B 1.22 B 1.22 B 1.28 B 1.18 B 1.12 B 1.14 B 1.13 B 1.15 B 1.23 B 1.16 B 1.64 B 1.59 B 1.57 B 1.35 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

20.5 B 19.7 B 16.2 B 15.9 B 14.6 B 13.1 B 10.5 B 11.1 B 9.27 B 9.13 B 7.09 B 7.57 B 7.64 B 6.5 B 5.33 B 5.75 B 5.36 B 5.06 B 5.74 B 5.95 B 5.34 B 4.79 B 4.93 B 5.72 B 4.41 B 4.28 B 4.64 B 4.83 B 4.3 B 4.51 B 3.95 B 4.51 B 4.15 B 4.35 B 3.8 B 4.52 B 4.07 B 4.25 B 3.88 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - -179 M -101 M -3.5 M -25.5 M -20.9 M -7.8 M 28.8 M -21.6 M -100 K -13.2 M 2.2 M -31.3 M -18.7 M -23.6 M 59.3 M 17.3 M 20.1 M -14.5 M 28.5 M -34 M -13 M -84.6 M -63.9 M -165 M 13 M 9.3 M 86 M -19.1 M -35.7 M 13.9 M 29.2 M 66.3 M 2.9 M 12.8 M 29.1 M - 47.2 M 43.2 M 43.4 M - 39.3 M 36.8 M 40.9 M - 38.1 M 35.5 M 37.8 M - 39.8 M 40.3 M 40.3 M - 47 M 43 M 45.3 M - 45 M 45.1 M 45.8 M - 47.2 M 47.5 M 74.5 M - 66.9 M 24.1 M

EBITDA

- 534 M 509 M -923 M 470 M 478 M 463 M -729 M 467 M 414 M 401 M -634 M 411 M 366 M 362 M -568 M 363 M 349 M 436 M -473 M 382 M 369 M 350 M -528 M 358 M 324 M 274 M -666 M 288 M 247 M 356 M -902 M 416 M 425 M 423 M -693 M 373 M 396 M 387 M - 1.15 B 759 M 386 M - 1.08 B 726 M 358 M - 1.04 B 697 M 349 M - 1.09 B 745 M 382 M - 1.12 B 748 M 386 M - 1.05 B 696 M 341 M - 990 M -645 M -299 M - 922 M 612 M

Operating Expenses

- 19.7 B 16.2 B - 14.6 B 13.1 B 10.5 B - 9.27 B 9.13 B 7.09 B - 7.64 B 6.5 B 5.33 B 5.75 B 5.36 B 5.06 B 5.74 B 5.95 B 5.34 B 4.79 B 4.93 B 5.72 B 4.41 B 4.28 B 4.64 B 3.28 B 2.79 B 2.99 B 2.75 B 3.09 B 2.74 B 2.76 B 2.45 B 3.29 B 2.92 B 3 B 2.83 B 3.24 B 2.8 B 2.96 B 2.69 B 3.24 B 2.72 B 2.8 B 2.56 B 2.99 B 2.92 B 2.86 B 2.59 B 3.43 B 3.03 B 3.2 B 3 B 3.44 B 3.1 B 3.25 B 3 B - - - - - - - - - - -

General and Administrative Expenses

3.12 B 3.43 B 2.93 B 3.13 B 2.74 B 2.75 B 2.47 B 2.42 B 2.1 B 2.12 B 1.95 B 1.93 B 1.8 B 1.93 B 1.75 B 1.64 B 1.61 B 1.63 B 1.56 B 1.59 B 1.58 B 1.69 B 1.58 B 1.55 B 1.57 B 1.45 B 1.55 B 1.7 B 1.41 B 1.59 B 1.52 B 1.69 B 1.46 B 1.49 B 1.34 B 1.11 B 1.58 B 1.73 B 1.57 B - 1.57 B 1.62 B 1.47 B - 1.58 B 1.64 B 1.52 B - 1.67 B 1.66 B 1.48 B - 1.65 B 1.87 B 1.65 B - 1.76 B 1.93 B 1.85 B - 1.92 B 2.04 B 1.79 B - 1.69 B 1.76 B 1.61 B - 1.7 B 1.71 B

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Eli Lilly and Company LLY
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Eli Lilly and Company plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 0.78 -4.87 % $ 179 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 2.01 -7.59 % $ 11.4 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 24.73 -1.9 % $ 783 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.32 1.02 % $ 2.52 M israelIsrael
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 2.05 -15.81 % $ 27.3 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
$ 76.99 0.03 % $ 997 M usaUSA
Curis Curis
CRIS
$ 0.44 -6.31 % $ 5.79 M usaUSA
CorMedix CorMedix
CRMD
$ 5.25 4.23 % $ 378 K usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
$ 3.07 -4.66 % $ 255 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.34 -1.36 % $ 60 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 10.9 -2.5 % $ 13.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 96.15 0.67 % $ 4.83 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 3.85 -2.66 % $ 1.18 B usaUSA
Dyadic International Dyadic International
DYAI
$ 0.29 -6.53 % $ 10.5 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 133.34 0.4 % $ 334 B usaUSA
Moderna Moderna
MRNA
$ 195.25 -2.05 % $ 76 B usaUSA
NuCana plc NuCana plc
NCNA
$ 0.75 4.39 % $ 8.42 B britainBritain
Novartis AG Novartis AG
NVS
$ 150.51 -0.47 % $ 292 B schweizSchweiz
Puma Biotechnology Puma Biotechnology
PBYI
$ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.69 -0.67 % $ 281 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 0.79 -2.58 % $ 36.6 M usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.87 -4.76 % $ 580 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 11.54 -5.18 % $ 7.95 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 4.65 -8.46 % $ 339 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 50.36 -1.93 % $ 3.26 B danmarkDanmark
Gossamer Bio Gossamer Bio
GOSS
$ 10.69 -4.81 % $ 2.44 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.14 -0.73 % $ 5.53 B spainSpain
Liquidia Corporation Liquidia Corporation
LQDA
$ 54.39 -3.96 % $ 4.68 B usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 47.8 -0.05 % $ 194 B britainBritain
MediciNova MediciNova
MNOV
$ 1.3 2.36 % $ 63.8 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
$ 56.23 -3.59 % $ 4.47 B usaUSA
Pulmatrix Pulmatrix
PULM
$ 1.24 -12.34 % $ 4.53 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.05 -3.67 % $ 70.7 M germanyGermany
Immunome Immunome
IMNM
$ 15.69 -5.54 % $ 1.37 B usaUSA
Immuron Limited Immuron Limited
IMRN
$ 0.9 5.87 % $ 208 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
$ 114.5 -1.19 % $ 22.4 B usaUSA
INmune Bio INmune Bio
INMB
$ 0.82 -8.41 % $ 20.3 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 14.88 0.24 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 920.38 -0.22 % $ 96.3 B usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 26.58 -2.37 % $ 4.25 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.06 -10.92 % $ 48.4 M israelIsrael
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
$ 4.68 -0.53 % $ 757 M usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
$ 2.73 -9.61 % $ 22.2 M usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 10.02 5.24 % $ 1.09 B usaUSA
Adagene Adagene
ADAG
$ 1.8 -10.56 % $ 106 M chinaChina
Denali Therapeutics Denali Therapeutics
DNLI
$ 18.43 1.29 % $ 3.18 B usaUSA
Pfizer Pfizer
PFE
$ 27.4 -0.62 % $ 156 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 10.56 -6.26 % $ 4.38 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 11.08 -0.81 % $ 100 M usaUSA